中國生命集團(08296.HK)擬2,888萬元購幹細胞研發公司三成股權
中國生命集團(08296.HK)公布,公司作為買方與賣方深圳富盈達信生物科技訂立買賣協議,據此賣方出售銷售股權,包括於GZRT廣州銳鑄生物科技的32%股權,總代價為2,888萬元。交易完成後,公司將擁有GZRT 32%已發行股本的權益,從而將擁有目標公司30.4%已發行股本的權益。
同時,目標公司廣東艾時代生物科技、GZRT及中國股權擁有人將實行重組及訂立VIE協議,據此,GZRT將可實際控制目標公司的財務及營運,並將有權享有目標公司產生的95%經濟利益及得益。
目標公司主要從事研發、生產及銷售幹細胞相關產品,包括但不限於幹細胞試劑盒,多種功能細胞和幹細胞培養基等及根據特定要求向客戶提供所有幹細胞技術服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.